Navigation Links
Panacea Pharmaceuticals Presents Three Papers Regarding Its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD
Date:11/8/2013

GAITHERSBURG, Md., Nov. 8, 2013 /PRNewswire-iReach/ -- Panacea Pharmaceuticals, Inc. presents three papers regarding its Nanoparticle-Based Therapeutic Cancer Vaccine at the Society for Immunotherapy of Cancer Annual Meeting at National Harbor, MD held November 8-10, 2013.  The three papers are titled:

Design, Development and Production of Nano-Particle-Based Anticancer Vaccine Targeting Human Aspartyl (Asparaginyl) β-Hydroxylase (HAAH)

Immunogenicity of a Lambda Phage-Based Anti-Cancer Vaccine Targeting HAAH

Inhibition of Tumor Growth in vivo by a Nanoparticle-Based Therapeutic Cancer Vaccine Targeting HAAH

(Photo: http://photos.prnewswire.com/prnh/20131108/MN13284)

Panacea has chosen to target the HAAH molecule for its proprietary therapeutic cancer vaccine because HAAH is expressed on cancer cells and not on non-cancer cells and its function is consistent with the etiology of cancer, i.e., is associated with growth, motility and invasiveness of cancer cells.  Monoclonal antibodies to HAAH have proven to have efficacy in both in vitro and in vivo tumor models.  HAAH is, however, an embryonic antigen, and as such, presents self-antigen tolerance.  The present vaccine entity is designed to overcome this tolerance by altering the presentation of the antigen and by providing an immunostimulant.  The nanoparticle is neutralized bacteriophage construct containing portions of HAAH, is easy to produce and is generally regarded as safe.  The nanoparticle vaccine carries 200-300 copies of HAAH fragments of approximately 25 kDa molecular weight on its surface.  The nanoparticle vaccine also contains DNA fragments that present the phage CpG motif to activate the MHC class II pathway.  We have engineered and manufactured the nanoparticle vaccine to meet FDA requirements for human use.

The nanoparticle therapeutic cancer vaccine targeting HAAH is clearly immunogenic in mice despite the high degree of homology to the human protein that makes the AAH resemble a self-antigen.  All three HAAH-lambda constructs were immunogenic and the antibody response was dose-dependent.  The nanoparticle therapeutic cancer vaccine targeting HAAH is effective in inhibition of tumor growth in mice under various conditions.  Each of the three constructs can inhibit tumor growth.  The vaccine can slow the growth of tumors prophylactically or by treatment simultaneous with or subsequent to establishment of solid tumors.

"We are excited to report that the nanoparticle-based therapeutic cancer vaccine targeting HAAH can be manufactured readily and is effective in tumor models", said Hossein Ghanbari, Ph.D., CEO and CSO of Panacea.  "The HAAH phage constructs are now being developed as clinical candidate vaccines and we are taking all the steps to prepare for an IND submission to FDA", said Steven Fuller, Ph.D., COO of Panacea.

Media Contact: Hossein Ghanbari, Panacea Pharmaceuticals, Inc., 240-305-4601, hag@panaceapharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Panacea Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
2. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
3. Vanda Pharmaceuticals Reports Third Quarter 2013 Results
4. Questcor Pharmaceuticals to Present at the 2013 Credit Suisse Annual Healthcare Conference
5. Imprimis Pharmaceuticals Inc. Announces Shift in Strategic Direction
6. Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2013 Financial Results
7. Cadence Pharmaceuticals Reports Third Quarter 2013 Financial Results
8. AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
9. Cumberland Pharmaceuticals Reports Third Quarter Financial Results
10. Jazz Pharmaceuticals Announces Third Quarter 2013 Financial Results
11. Top Trial Firm Cohen, Placitella & Roth, PC Investigating Ariad Pharmaceuticals, Inc., for Suspending Sales of its Leukemia Drug Iclusig
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2019)... , ... October 11, 2019 , ... Based on data ... a 9 percent increase in deceased organ donors over 2018. Through August 31, 7,786 ... Transplantation Network (OPTN) national database . At this pace, the Association of Organ ...
(Date:10/10/2019)... ... October 10, 2019 , ... ... Cocktail Reception on Thursday, September 26, at the Westchester Country Club in Rye. ... unwavering support of the organization and its mission. , “In Celebration” featured live ...
(Date:10/8/2019)... Pa. (PRWEB) , ... October 09, 2019 , ... “When ... the emotions, frustrations, and the realities of the HEMS world through telling the real ... Helicopter Pilot” is the creation of published author Jay A. Humphrey, an EMS helicopter ...
Breaking Medicine Technology:
(Date:10/17/2019)... SANTA BARBARA, Calif. (PRWEB) , ... October 17, 2019 , ... ... one ingenious magnetic roller case, quickly broke its campaign goal– raising more than $20,000 ... see the response from the crowdfunding community, who’ll be the first to enjoy the ...
(Date:10/17/2019)... ... , ... Whole Foods Market, along with Austin leaders, has joined forces with ... an in-depth assessment by the Blue Zones team of the Austin Metro area and ... to live, work, grow up, and grow old. , Blue Zones is based on ...
(Date:10/15/2019)... (PRWEB) , ... October 15, 2019 , ... ... with FDA’s Most Recent IFU Guidance , **An FDAnews Webinar**, Tuesday, October 29, ... Instructions for Use (IFU) guidance have on new drug applications and biologics license ...
(Date:10/15/2019)... ... , ... Nashville Fertility Center (NFC) is proud to announce that Kristin ... In addition to treating general infertility, Dr. Van Heertum offers expertise in fertility surgery ... to Dr. Van Heertum joining the practice and believes she is the perfect fit. ...
(Date:10/11/2019)... DALLAS (PRWEB) , ... October 11, 2019 , ... A ... Alliance (STA) new headquarters facility by general contractors Adolfson & Peterson Construction. The event ... of 2020 at 8190 Midtown Road in Dallas. The first of its kind in ...
Breaking Medicine News(10 mins):